HOLX logo

HOLX

Hologic, Inc.NASDAQHealthcare
$75.65+0.07%OpenMarket Cap: $16.89B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

31.05

PEG

P/B

3.24

P/S

4.09

EV/EBITDA

17.00

DCF Value

$104.90

FCF Yield

5.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.8%

Operating Margin

17.5%

Net Margin

13.2%

ROE

11.0%

ROA

10.9%

ROIC

7.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 2026$1.05B$179.1M$0.79
Q4 2025$1.05B$187.3M$0.83
FY 2025$4.10B$565.7M$2.49
Q3 2025$1.02B$194.9M$0.86

Analyst Ratings

View All
Argus ResearchHold
2026-01-12
Evercore ISI GroupIn Line
2026-01-05
Morgan StanleyEqual Weight
2025-11-11
MizuhoNeutral
2025-10-23
Raymond JamesMarket Perform
2025-10-22

Trading Activity

Insider Trades

View All
Liddy Anne M.officer: General Counsel
SellMon Mar 02
Wendell Amy McBridedirector
SellMon Mar 02
Stewart Stacey D.director
SellMon Mar 02
Stamoulis Christianadirector
SellMon Mar 02
Mohtashami Nanazdirector
SellMon Mar 02

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

0.70

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Peers